利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.011 秒)

    BIOMARKERS FOR ALZHEIMER'S DISEASE
    3.
    发明申请
    BIOMARKERS FOR ALZHEIMER'S DISEASE 审中-公开
    阿尔茨海默病的生物标志物

    公开(公告)号：US20130029864A1

    公开(公告)日：2013-01-31

    申请号：US13499546

    申请日：2010-10-01

    申请人： Angelika Lueking ,  Stefan Müllner ,  Charlotte Teunissen ,  Jens Wiltfang

    发明人： Angelika Lueking ,  Stefan Müllner ,  Charlotte Teunissen ,  Jens Wiltfang

    IPC分类号： C40B30/04 ,  C40B40/08

    CPC分类号： G01N33/6896 ,  G01N2800/2821

    摘要： The invention relates to novel marker sequences for Alzheimer's disease, in particular Alzheimer's dementia, and their diagnostic use including a screening method in order to identify potential drugs for the treatment/prophylaxis of Alzheimer's disease by means of the said novel marker sequences. Moreover, the invention relates to a diagnostic device comprising said novel marker sequences for diagnosing Alzheimer's disease, particularly a protein array (chip) and its use hereto.

    摘要翻译： 本发明涉及阿尔茨海默病，特别是阿尔茨海默氏痴呆的新型标记序列及其诊断用途，包括筛选方法，以通过所述新型标记序列鉴定用于治疗/预防阿尔茨海默氏病的潜在药物。 此外，本发明涉及包含用于诊断阿尔茨海默病的新型标记序列，特别是蛋白质阵列（芯片）的诊断装置及其用途。

    Isoxazole and crotonamide derivatives and their use as pharmaceuticals and diagnostics
    4.
    发明授权
    Isoxazole and crotonamide derivatives and their use as pharmaceuticals and diagnostics 有权
    异恶唑和巴豆酰胺衍生物及其作为药物和诊断用途

    公开(公告)号：US06265588B1

    公开(公告)日：2001-07-24

    申请号：US09580625

    申请日：2000-05-30

    申请人： Stefan Müllner ,  Bernd Kirschbaum ,  Wilfried Schwab

    发明人： Stefan Müllner ,  Bernd Kirschbaum ,  Wilfried Schwab

    IPC分类号： C07D26108

    CPC分类号： G01N33/68 ,  C07C255/23 ,  C07D261/18 ,  G01N33/54393 ,  G01N33/558 ,  G01N33/94

    摘要： A compound of the formula where R1 is the radical of the formula II or III is suitable for the production of a pharmaceutical for the treatment of inflammations, carcinomatous diseases, or autoimmune diseases. A compound of the formula IV is suitable for the production of specific antibodies against a compound of the formula I for the discovery of specific-binding proteins from cell extracts, serum, blood, or synovial fluids, for the purification of proteins, for the modification of microtiter plates, or for the preparation of chromatography material, in particular of affinity chromatography material, and for use in diagnostics.

    摘要翻译： 制剂R1的化合物是式II或III的基团，其适用于制备用于治疗炎症，癌性疾病或自身免疫性疾病的药物。 式IV化合物适用于生产针对式I化合物的特异性抗体，用于从细胞提取物，血清，血液或滑液中发现特异性结合蛋白，用于蛋白质的纯化，用于修饰 微量滴定板，或用于制备色谱材料，特别是亲和层析材料，并用于诊断。

    Disrupting cells and/or tissue in solid state in presence of solid denaturing substance
    8.
    发明授权
    Disrupting cells and/or tissue in solid state in presence of solid denaturing substance 失效
    在固体变性物质的存在下破坏固体的细胞和/或组织

    公开(公告)号：US06589785B1

    公开(公告)日：2003-07-08

    申请号：US09581563

    申请日：2000-07-31

    申请人： Stefan Müllner ,  Thomas Neumann

    发明人： Stefan Müllner ,  Thomas Neumann

    IPC分类号： C12N106

    CPC分类号： C12N15/1003 ,  C12N1/06

    摘要： A method for disrupting frozen cells and/or tissue in a solid, frozen state in the presence of a solid denaturing substance is provided. The method comprises providing frozen cells and/or tissue in frozen solid form, adding thereto the solid denaturing substance in sold form, and applying mechanical force thereto for disruption of the frozen cells and/or tissue. The frozen cells and/or tissue include muscle cells and/or muscle tissue, wheat cells and/or wheat tissue, and maize cells and/or maize tissue. Further, the solid, denaturing substance in solid form is a crystalline substance and can be selected from urea, thiourea, guanidium chloride, guanidium thiocyanate and ammonium sulfate. Also the solid, denaturing substance in solid form is added to the frozen cells and/or tissue in frozen form in an approximately 1 to 20 fold (w/w) excess.

    摘要翻译： 提供了在固体变性物质存在下破坏固体，冷冻状态的冷冻细胞和/或组织的方法。 该方法包括以冷冻固体形式提供冷冻细胞和/或组织，向其中以出售形式加入固体变性物质，并施加机械力以破坏冷冻的细胞和/或组织。 冷冻细胞和/或组织包括肌肉细胞和/或肌肉组织，小麦细胞和/或小麦组织，以及玉米细胞和/或玉米组织。 此外，固体形式的固体变性物质是结晶物质，可以选自脲，硫脲，氯化胍，硫氰酸胍和硫酸铵。 此外，将固体形式的固体变性物质以约1至20倍（w / w）的过量加入到冷冻细胞和/或冷冻形式的组织中。